Clinical Trials
7 trialsNCT01627041 2026-04-27
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT04055844 2023-11-07
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01607645 2017-03-31
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02029417 2016-05-09
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00114257 2013-02-11
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed